AI-powered research site
Nobody does with AI what we do. AI finds the study. AI finds the patients. AI answers feasibility in seconds. And we publish the numbers to prove it.
Amavita Research is an AI-driven clinical research site. Nobody does with AI what we do: our Trial Radar system scans the world's public trial registries, regulatory filings, investor disclosures, funding awards, patent records, conference programs, coverage decisions and clinical-hiring signals every single day — so we find your study while the site-selection window is still open, not after it closes. Then our AI patient-feasibility technology identifies trial-eligible patients directly from our own electronic health record. Discovery and enrollment, both powered by AI, both under one roof in Miami.
Trial Radar watches ClinicalTrials.gov, the EU CTIS portal, WHO ICTRP and national registries, FDA and EMA filings, SEC investor disclosures, NIH and EU grant awards, USPTO patent assignments, first-in-human conference abstracts and clinical-operations hiring signals — daily. When a study in our therapeutic scope appears, we reach out to the sponsor while sites are still being selected.
No other site in Miami is using AI patient-feasibility technology to identify patients from their own EMR. We are activating AI prescreening across our electronic health record, so our feasibility answers come from real patient data — 18,000+ active cardiology patients — not from guesses or rented databases.
We can complete feasibility questionnaires in seconds because we use AI. Nobody else does this. Protocol criteria run against our own patient population — real counts, real fast — instead of weeks of manual chart review.
No other site in Miami discloses the number of active patients it has. We do: 18,000+ active cardiology patients, verified October 2026. Sponsors deserve to know the size of the population behind a feasibility commitment, so we publish ours.
Trial Radar watches eight families of public signals — the same sources sponsors, investors and regulators publish into. When they point at an upcoming study in our scope, we act while the site-selection window is still open.
ClinicalTrials.gov, EU CTIS, WHO ICTRP and national registries (Japan, Korea, Brazil, EU member states and more) — new studies and status flips, tracked daily.
FDA designations, post-marketing requirements and approval milestones; EMA PRIME, orphan designations and committee activity.
SEC filings — financing rounds, IPO pipeline tables and trial-timing statements that reveal when a first trial is coming, 6–18 months out.
NIH SBIR/STTR awards, EU EIC Accelerator and health-cluster funding, CIRM, BARDA and ARPA-H — money is the earliest public signal of a coming trial.
University-to-startup technology licenses and patent assignments that mark the moment an academic program becomes a company with a trial ahead.
First-in-human conference abstracts (TCT, EuroPCR, SNMMI, neuromodulation meetings), sponsor pipeline announcements and trial-in-progress presentations.
CMS IDE coverage, Coverage with Evidence Development and transitional coverage programs that precede device trial activity.
Clinical-operations hiring — the most reliable precursor to a first trial. When a startup hires its first clinical project manager, a trial is coming.
18,000+
active cardiology patients
8
signal families scanned
Daily
discovery scans
100%
human-reviewed outreach
Trial Radar is Amavita Research's AI-powered study-sourcing system. It scans public trial registries, regulatory filings, investor disclosures, funding awards, patent records, conference programs, coverage decisions and clinical-hiring signals every day to find upcoming industry-sponsored trials while site selection is still open.
We are activating AI prescreening technology across our own electronic health record. The system identifies trial-eligible patients from real clinical data — 18,000+ active cardiology patients — so feasibility commitments are grounded in the actual population, not estimates. No other site in Miami uses AI patient-feasibility technology on its own EMR.
18,000+ active cardiology patients, verified October 2026. We publish the number because sponsors deserve to know the population behind a feasibility commitment. No other site in Miami discloses its active patient count.
Start with a sponsor consultation. Our team reviews your protocol against our patient population and capabilities, confirms feasibility from real EHR data, and moves to CDA and site qualification. Contact us through the sponsor consultation page.
Prefer to start with capabilities? For sponsors